Tilray Brands, Inc. - Common Stock (TLRY)

Cannabis news this week: Congress revives cannabis reform, Slovenia leads Europe, Tyson takes charge and science backs cannabis for cancer care.

Tilray shares are trading lower by 6.2% during Thursday's session. The company on Thursday announced plans to implement a reverse stock split.

Tilray shares fall 6.8% after announcing a proposed reverse stock split ahead of a June 10 shareholder vote.

Tilray Brands Inc. (NASDAQ: TLRY) has launched its first medical cannabis edibles in Australia through Tilray Medical. The new sugar-free, vegan Good Supply Pastilles offer THC and CBD options, enhancing patient access to plant-based therapies.

The past, present and futur eof the Canasian cannabis sector.

Cannabis news of the week: Germany holds CanG, US delays, Chile bill; Italy hemp ban; SNDL expands, Tilray cuts outlook, US sales forecast –$21 B.

The past, present, and future of the Canadian cannabis sector.

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) fell 19.7% in the afternoon session after the company reported weak fiscal third-quarter 2025 results that missed analysts' sales and EBITDA estimates, signaling ongoing challenges in growing its top line. 

Tilray Brands missed Q3 revenue expectations and lowered FY25 outlook, while beverage and wellness units posted year-over-year revenue increases.

Beer, wine, and spirits company Constellation Brands (NYSE:STZ) will be reporting results tomorrow after market close. Here’s what you need to know.

Cannabis company Tilray Brands (NASDAQ:TLRY) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $185.8 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 2% below analysts’ estimates. Its non-GAAP loss of $0 per share was significantly above analysts’ consensus estimates.